So Phase 3 is going to be similar to phase 2 that the primary endpoints need to be successful ?
1. Absolute change from baseline in inflammatory and absolute change from baseline in noninflammatory lesion at Week 12; and
2. Proportion of patients with an Investigators Global Assessment (IGA) of “clear” or “almost clear” and at least a 2-grade improvement in IGA from baseline at Week 12.
Ann: BTX 1503 End of Phase 2 Milestone with FDA, page-11
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 919 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 25000 | 1 |
View Market Depth
| Last trade - 09.58am 10/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable